drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T cells)
drug_description
Autologous, gene-modified CAR T-cell therapy that dual-targets CD19 and CD20 to induce antigen-dependent T-cell activation, proliferation, cytokine release, and cytotoxic elimination of malignant B cells; administered as a single-dose infusion after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express chimeric antigen receptors that co-target CD19 and CD20; antigen engagement activates CAR signaling leading to T-cell activation, proliferation, cytokine release, and cytotoxic elimination of malignant B cells (on-target B-cell aplasia).
drug_name
LUCAR-G39D
nct_id_drug_ref
NCT06395870